A Phase 2 interventional study of CIN-107 and Placebo in Uncontrolled Hypertension and Chronic Kidney Diseases, sponsored by AstraZeneca. Completed at 71 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-05-20.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Renal Insufficiency, Chronic by AstraZeneca — 6 open to participants now, 11 under way, 5 of them phase 3. Renal Insufficiency, Chronic · AstraZeneca.
Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, this one is the 17th largest by enrollment of the 38 interventional ones that give a count, is one of 9 that started in 2022, is one of 9 in phase 2, and was the 29th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →6 of the 54 studies in Renal Insufficiency, Chronic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 24 more countries
Ages 18–99
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 18+
AstraZeneca · Sites in China
AstraZeneca · Sites in United States
Ages 18–75 · Healthy volunteers
AstraZeneca · Sites in United States, Argentina, Australia and 39 more countries
Ages 18+
By country, each count listing its studies:
Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 9 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 195 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 170 across the 38 interventional studies, 4,000 across the 16 observational. Of the 43 that completed or were terminated, 18 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
3 of the studies in Renal Insufficiency, Chronic by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT07024823AstraZenecaA Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants | 2027-01-29 |
| NCT06610526AstraZenecaA Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease | 2027-05-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of CIN-107 for the treatment of hypertension in patients with uncontrolled hypertension (uHTN) and Chronic Kidney Disease (CKD).
This randomized, double-blind, placebo-controlled will evaluate the efficacy and safety of CIN-107 in patients with uHTN and CKD. Approximately 200 patients will be randomized in a 1:1:1 ratio into 1 of the 3 treatment groups (placebo, low dose treatment strategy and high dose treatment strategy).
The study will consist of the following 3 periods:
Patients will complete the study in approximately 8 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will take oral tablets of CIN-107 for 26 weeks. The dose strength may be titrated within 6 weeks.
Drug: CIN-107
Patients will take oral tablets of CIN-107 for 26 weeks. The dose strength may be titrated within 6 weeks.
Drug: CIN-107
Patients will take oral tablets of Placebo for 26 weeks. The dose strength may be titrated within 6 weeks.
Drug: Placebo
Patients will take CIN-107 tablets by mouth once daily.
Patients will take placebo tablets by mouth once daily.
Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) of Pooled CIN-107 and Placebo
Mean change in seated SBP from baseline to Week 26 of pooled CIN-107 and placebo was assessed.
Time frame: At Week 26
Change From Baseline in SBP in CIN-107 Compared to Placebo in Participants Assigned to the High-dose Strategy Group
Mean change in seated SBP from baseline to Week 26 of high-dose CIN-107 dosing group and placebo was assessed.
Time frame: At Week 26
Change From Baseline of SBP in CIN-107 Compared to Placebo in Participants Assigned to the Low-dose Strategy Group
The mean change in seated SBP from baseline to Week 26 of low-dose CIN-107 dosing group and placebo was assessed.
Time frame: At Week 26
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
The safety and tolerability of CIN-107 in participants with uncontrolled hypertension (uHTN) and chronic kidney disease (CKD) was assessed. Adverse events of special interest (AESI) include any hypotension events, abnormal potassium or sodium laboratory values that require clinical intervention.
Time frame: From randomization (Day 1) until the end of Follow up period (approximately 8 months)
This study was conducted from 29 April 2022 to 02 May 2024 at 78 sites in the United States.
| Milestone | CIN-107 Low Dosing Strategy Group | CIN-107 High Dosing Strategy Group | Placebo |
|---|---|---|---|
| Started | 65 | 64 | 66 |
| Completed | 53 | 54 | 51 |
| Not completed | 12 | 10 | 15 |
| Withdrew: Adverse event | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 3 | 3 | 2 |
| Withdrew: Inclusion/exclusion criteria not met | 1 | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 4 | 11 |
| Withdrew: Other | 0 | 0 | 1 |
Mean change in seated SBP from baseline to Week 26 of pooled CIN-107 and placebo was assessed.
| Millimeters of mercury (mmHg) | CIN-107 Treatment Groups Pooled | Placebo |
|---|---|---|
| Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) of Pooled CIN-107 and Placebo | -15.22 ± 1.532 | -7.15 ± 2.231 |
Mean change in seated SBP from baseline to Week 26 of high-dose CIN-107 dosing group and placebo was assessed.
| mmHg | CIN-107 High Dosing Strategy Group | Placebo |
|---|---|---|
| Change From Baseline in SBP in CIN-107 Compared to Placebo in Participants Assigned to the High-dose Strategy Group | -14.37 ± 2.117 | -7.16 ± 2.233 |
The mean change in seated SBP from baseline to Week 26 of low-dose CIN-107 dosing group and placebo was assessed.
| mmHg | CIN-107 Low Dosing Strategy Group | Placebo |
|---|---|---|
| Change From Baseline of SBP in CIN-107 Compared to Placebo in Participants Assigned to the Low-dose Strategy Group | -16.14 ± 2.186 | -7.16 ± 2.233 |
The safety and tolerability of CIN-107 in participants with uncontrolled hypertension (uHTN) and chronic kidney disease (CKD) was assessed. Adverse events of special interest (AESI) include any hypotension events, abnormal potassium or sodium laboratory values that require clinical intervention.
| Participants | CIN-107 Low Dosing Strategy Group | CIN-107 High Dosing Strategy Group | Placebo |
|---|---|---|---|
| All TEAEs | 48 | 52 | 35 |
| All TEAEs, related to treatment | 23 | 31 | 14 |
| Any TEAE with outcome = Death | 0 | 0 | 0 |
| Any TEAE with outcome = Death, related to treatment | 0 | 0 | 0 |
| Any TEAE leading to dose interruption | 20 | 23 | 13 |
| Any TEAE leading to dose interruption, related to treatment | 10 | 10 | 4 |
| Any TEAE leading to discontinuation of treatment | 10 | 11 | 5 |
| Any TEAE leading to discontinuation of treatment, related to treatment | 7 | 8 | 3 |
| Any TEAE leading to discontinuation of study | 0 | 2 | 1 |
| Any TEAE leading to discontinuation of study, related to treatment | 0 | 1 | 1 |
| All treatment emergent serious adverse events (TESAEs) | 7 | 5 | 2 |
| All TESAEs, related to treatment | 2 | 1 | 1 |
| Any TESAE with outcome = Death | 0 | 0 | 0 |
| Any TESAE with outcome = Death, related to treatment | 0 | 0 | 0 |
| Any TESAE leading to dose interruption | 2 | 1 | 1 |
| Any TESAE leading to dose interruption, related to treatment | 0 | 0 | 1 |
| Any TESAE leading to discontinuation of treatment | 2 | 2 | 1 |
| Any TESAE leading to discontinuation of treatment, related to treatment | 2 | 1 | 0 |
| Any TESAE leading to discontinuation of study | 0 | 1 | 0 |
| Any TESAE leading to discontinuation of study, related to treatment | 0 | 0 | 0 |
| Treatment emergent AESIs | 11 | 12 | 4 |
Collected over From randomization (Day 1) until the end of Follow up period (approximately 8 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CIN-107 Low Dosing Strategy Group | 0/65 (0%) | 7/65 (10.8%) | 47/65 (72.3%) |
| CIN-107 High Dosing Strategy Group | 0/63 (0%) | 5/63 (7.9%) | 52/63 (82.5%) |
| Placebo | 0/64 (0%) | 2/64 (3.1%) | 35/64 (54.7%) |
| Event | CIN-107 Low Dosing Strategy Group | CIN-107 High Dosing Strategy Group | Placebo |
|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 3/65 | 0/63 | 0/64 |
| HyperkalaemiaMetabolism and nutrition disorders | 2/65 | 1/63 | 0/64 |
| Eye infectionInfections and infestations | 0/65 | 1/63 | 0/64 |
| Nodal arrhythmiaCardiac disorders | 0/65 | 1/63 | 0/64 |
| Deep vein thrombosisVascular disorders | 0/65 | 1/63 | 0/64 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/65 | 1/63 | 0/64 |
| HaemorrhoidsGastrointestinal disorders | 0/65 | 1/63 | 0/64 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/65 | 1/63 | 0/64 |
| ProctalgiaGastrointestinal disorders | 0/65 | 1/63 | 0/64 |
| Rectal haemorrhageGastrointestinal disorders | 0/65 | 1/63 | 0/64 |
| Event | CIN-107 Low Dosing Strategy Group | CIN-107 High Dosing Strategy Group | Placebo |
|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 21/65 | 32/63 | 3/64 |
| Blood creatinine increasedInvestigations | 11/65 | 15/63 | 5/64 |
| Renal impairmentRenal and urinary disorders | 2/65 | 5/63 | 3/64 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/65 | 5/63 | 2/64 |
| Glomerular filtration rate decreasedInvestigations | 2/65 | 4/63 | 5/64 |
| Chronic kidney diseaseRenal and urinary disorders | 0/65 | 0/63 | 4/64 |
| Orthostatic hypotensionVascular disorders | 2/65 | 2/63 | 4/64 |
| HyponatraemiaMetabolism and nutrition disorders | 4/65 | 1/63 | 0/64 |
| Blood potassium increasedInvestigations | 4/65 | 0/63 | 0/64 |
| Lipase increasedInvestigations | 2/65 | 3/63 | 1/64 |
Intent-to-treat population (ITT) included all participants randomized into the study. Treatment classification was based on the randomized treatment assignment.
| Age, Continuous(Years) | CIN-107 Low Dosing Strategy Group | CIN-107 High Dosing Strategy Group | Placebo | Total |
|---|---|---|---|---|
| Age | 67.2 ± 12.63 | 66.5 ± 11.02 | 65.6 ± 10.79 | 66.4 ± 11.46 |
| Sex: Female, Male(Participants) | CIN-107 Low Dosing Strategy Group | CIN-107 High Dosing Strategy Group | Placebo | Total |
|---|---|---|---|---|
| Female | 23 | 21 | 19 | 63 |
| Male | 42 | 43 | 47 | 132 |
| Race/Ethnicity, Customized(Participants) | CIN-107 Low Dosing Strategy Group | CIN-107 High Dosing Strategy Group | Placebo | Total |
|---|---|---|---|---|
| Race — Asian | 4 | 3 | 5 | 12 |
| Race — Black or African American | 19 | 24 | 20 | 63 |
| Race — White | 41 | 34 | 38 | 113 |
| Race — Other | 0 | 1 | 2 | 3 |
| Race — Not Reported | 1 | 2 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
Ran from Apr 2022 to primary completion in May 2024, 24 months.
Results were first posted in May 2025, 1 year after primary completion.
Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 24 months is above that.
Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baxdrostat
Renal Insufficiency, Chronic →